Bionano第三季度收入跃升6%，超过2025年指导范围

2025-11-14 06:51

Bionano Genomics (BNGO) is up ~6% in after-hours trading Thursday after reporting Q3 financial results that beat on revenue and reiterating full-year revenue guidance that includes the consensus.
Full-year revenue is projected at $26M-$30M. Consensus is $28.45M. Q4 revenue, however, is not expected to include the consensus of $8.36M with a range of $7.5M-$7.9M.
In Q3, Bionano significantly reduced its year-over-year next loss to (~$8.5M) from (~$44.2M).
The company ended the quarter (Sept. 30) with cash, cash equivalents, and investments of ~$21.6M compared to ~$9.5M on Dec. 31, 2024.

More on Bionano Genomics